

Subject name	Address	Effective date
FRAUD/KICKBACKS/PROHIBITED ACTS/SETTLEMENT AGREEMENTS		
KUMAR, ANIL	MONMOUTH JUNCTION, NJ	9/21/2004
KUMAR, SAROJ	MONMOUTH JUNCTION, NJ	9/21/2004
OWNED/CONTROLLED BY CONVICTED ENTITIES		
BFK TRANSIT, INC	MILWAUKEE, WI	11/18/2004
EMMETT FOOT & ANKLE CLINIC	EMMETT, ID	11/18/2004
KAZEM S SADATI DDS, PA	MIAMI LAKES, FL	11/18/2004
MEDICAL SOUTH, INC	COLUMBUS, MS	11/18/2004
ONTARIO FOOT & ANKLE CLINIC	ONTARIO, OR	11/18/2004
PALM BEACH TOTAL HEALTH CARE, INC	BOYNTON BEACH, FL	11/18/2004
UNIVERSAL PLACEMENT, INC	LOS ANGELES, CA	11/18/2004
DEFAULT ON HEAL LOAN		
CONLEY, PAMELA	NEW ORLEANS, LA	9/14/2004
FARHAT, HASSAN	STATEN ISLAND, NY	11/18/2004
LAM, THE	SAN JOSE, CA	11/18/2004
SHEEHY, DANIEL	MIDDLETOWN, CA	11/18/2004

Dated: November 3, 2004.

Katherine B. Petrowski,

Director, Exclusions Staff, Office of Inspector General.

[FR Doc. 04-25251 Filed 11-12-04; 8:45 am]

BILLING CODE 4150-04-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Proposed Collection; Comment Request; Outcome Evaluation of the Fogarty International Center (FIC) AIDS International Training and Research Program (AITRP)

SUMMARY: In compliance with the requirement of Section 3506(c)(2)(A) of

the Paperwork Reduction Act of 1995, for opportunity for public comment on proposed data collection projects, the Fogarty International Center (FIC), the National Institutes of Health (NIH), will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval.

Proposed Collection: Title: Outcome Evaluation of the FIC AIDS International Training and Research Program (AITRP). *Type of Information Collection Request:* New. *Need and Use of Information Collection:* This study will assess the outputs, outcomes and impacts of the AIDS International Training and Research Program (AITRP). The findings will provide valuable information concerning: (1)

The research capacity development, collaboration, public health, and public policy outputs, outcomes, and impacts of AITRP at the program level and country level; (2) management and policy implications for the AITRP program based on trainee responses. *Frequency of Response:* Once. *Affected Public:* none. *Type of Respondents:* Trainees involved in the AITRP program. There are no Capital Costs to report. There are no Operating or Maintenance Costs to report.

Type of respondents	Estimated number of respondents	Estimated number of responses per respondent	Average burden hours per response	Estimated total annual burden hours requested
Trainees	300	1	1	300
Total	300	300		

Type of respondents	Estimated number of respondents	Frequency of response	Average hourly wage rate	Respondent cost
Trainees	300	1	\$5.00/hr	\$1500
Total Cost				\$1500

Request for Comments: Written comments and/or suggestions from the public and affected agencies are invited on one or more of the following points:

(1) Whether the proposed collection of information is necessary for the proper performance of the function of the agency, including whether the

information will have practical utility; (2) the accuracy of the agency's estimate of the burden of the proposed collection of information, including the validity of

the methodology and assumptions used; (3) ways to enhance the quality, utility, and clarity of the information to be collected; and (4) ways to minimize the burden of the collection of information on those who are to respond, including the use of appropriate automated, electronic, mechanical, or other technological collection techniques or other forms of information technology.

FOR FURTHER INFORMATION CONTACT: To request more information on the proposed project or to obtain a copy of the data collection plans and instruments, contact Dr. Linda Kupfer, Fogarty International Center, National Institutes of Health, 16 Center Drive, Building 16, Bethesda, MD 20892-6705 or call non-toll-free number 301-496-3288 or E-mail your request, including your address to: Kupferl@mail.nih.gov.

Comments Due Date: Comments regarding this information collection are best assured of having their full effect if received within 60-days of the date of this publication.

Dated: November 5, 2004.

Richard Miller,

Executive Officer, FIC, National Institutes of Health.

[FR Doc. 04-25281 Filed 11-12-04; 8:45 am]

BILLING CODE 4140-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, Public Health Service, DHHS.

ACTION: Notice.

SUMMARY: The inventions listed below are owned by an agency of the U.S. Government and are available for licensing in the U.S. in accordance with 35 U.S.C. 207 to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing.

ADDRESSES: Licensing information and copies of the U.S. patent applications listed below may be obtained by writing to the indicated licensing contact at the Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, Maryland 20852-3804; telephone: 301/496-7057; fax: 301/402-0220. A signed

Confidential Disclosure Agreement will be required to receive copies of the patent applications.


Metal Chelators and Target-Moiety Complexes for Imaging

Martin W. Brechbiel and Thomas Clifford (NCI).


U.S. Provisional Application filed 23 Aug 2004 (DHHS Reference No. E-317-2004).

Licensing Contact: Michael Shmilovich; 301/435-5019; shmilovm@mail.nih.gov.

Available for licensing and commercial development are bifunctional metal chelators, metal chelator-targeting moiety complexes, metal chelator-targeting moiety-metal conjugates, kits, and methods of preparing them. These chelators are useful in diagnosing and/or treatment of cancer and thrombosis. The metal chelators may be used in conventional and solid-phase synthetic methods to form targeting moieties (e.g., peptides, and Starburst polyamidoamine dendrimers (PAMAM), capable of conjugating diagnostic and/or therapeutic metals. The formulae for two such chelators is shown below:



I



II

Anti-HIV Peptide Secreting Bacteria: Therapeutics and Methods of Use

Dean Hamer (NCI).

U.S. Provisional Application No. 60/604,051 filed 25 Aug 2004 (DHHS Reference No. E-233-2004/0-US-01).

Licensing Contact: Michael Shmilovich; 301/435-5019; shmilovm@mail.nih.gov.

Available for licensing and commercial development are genetically